Skip to main content
. 2018 Apr 19;78(7):781–785. doi: 10.1007/s40265-018-0907-5

Key clinical trials of intravenous ibalizumab (TaiMed Biologics)

Drug(s) Indication Phase Patients Status Location (s) Identifier
Ibalizumab HIV-1 infection Ia 30 Completed USA N/A
Ibalizumab plus optimised background regimen Treatment naïve or previously treated HIV-1 infection Ib 22 Completed USA N/A
Ibalizumab plus optimised background regimen, placebo Previously treated HIV-1 infection IIa 82 Completed USA, Puerto Rico, Canada NCT00089700, TNX-355.03
Ibalizumab plus optimised background regimen Previously treated HIV-1 infection IIb 113 Completed USA, Puerto Rico NCT00784147, TMB-202
Ibalizumab plus optimised background regimen Previously treated HIV-1 infection, PI-IND extension of IIb II 56 Completed USA NCT01056393
Ibalizumab plus optimised background regimen Multidrug resistant HIV-1 infection III 40 Completed USA, Puerto Rico, Taiwan NCT02475629, TMB-301
Ibalizumab plus optimised background regimen Multidrug resistant HIV-1 infection III 27 Ongoing USA, Puerto Rico NCT02707861, TMB-311